drugset / Trial / NCT00804336
Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
Phase 1
Completed
22 enrolled
Dana-Farber Cancer Institute
Beth Israel Deaconess Medical Center · collabBrigham and Women's Hospital · collabMassachusetts General Hospital · collabNovartis · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this research study is to determine the safety of the combination of SOM230 and RAD001, as well as determine the highest dose of this combination that can be given to people safely. SOM230 is an investigational drug that is similar to Sandostatin LAR. Sandostatin is an approved drug for the use of treating symptoms of neuroendocrine tumors. SOM230 has shown to be effective in patients who have become resistant to Sandostatin and may also stop cancer cells from growing. RAD001 is an investigational drug that also may stop cancer cells from growing.
Timeline
- Start
- 2008-10
- Primary completion
- 2014-09
- Completion
- 2015-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Everolimus | Small molecule | 5 mg | Oral |
| Subject | Everolimus | Small molecule | 10 mg | Oral |
| Subject | Pasireotide | Other / unclassified | 40 mg | Subcutaneous |
| Subject | Pasireotide | Other / unclassified | 60 mg | Subcutaneous |